BiotechTube
Home/Pipeline/PDC-Docetaxel (inferred)

PDC-Docetaxel (inferred)

Oncology (unspecified)

Phase 1Active

Key Facts

Indication
Oncology (unspecified)
Phase
Phase 1
Status
Active
Company
PDC Biotech

About PDC Biotech

PDC Therapeutics is a private, pre-revenue biotech leveraging its proprietary Sagitta® biodegradable polymer-drug conjugation platform to develop targeted nanomedicines. The company is at a clinical-stage, with an abstract accepted for the ASCO 2025 meeting, indicating progress in oncology. Led by co-founder and award-winning scientist Prof. Rana Sanyal, the company operates from Basel, Switzerland, and engages in co-development programs with multinational pharmaceutical partners.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a